ICU Medical, Inc.(ICUI) Stock Research - Grey Stern Research
Loading...

ICU Medical, Inc. (ICUI) Stock Analysis

$138.67 (-0.34%)

ICUI Financial Performance


Use the table below to view ICU Medical, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $138.67 -
52 Week Low $93.36 -
52 Week High $196.26 -
Market Cap $3.4 Billion 5/12
Gross Margin 36% 11/12
Profit Margin -4% 8/12
EBITDA margin 14% 5/12
Q4 - 2024 Revenue $629.8 Million 6/12
Q4 - 2024 Earnings -$23.8 Million 11/12
Q4 - 2024 Free Cash Flow $13.6 Million 6/12
Trailing 4 Quarters Revenue $2.4 Billion 6/12
Trailing 4 Quarters Earnings -$117.7 Million 10/12
Quarterly Earnings Growth -39% 10/12
Annual Earnings Growth -2677% 12/12
Quarterly Revenue Growth 7% 6/12
Annual Revenue Growth 6% 7/12
Cash On Hand $308.6 Million 5/12
Short Term Debt $51.0 Million 4/12
Long Term Debt $1.5 Billion 3/12

ICU Medical, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare ICU Medical, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 7/12
PS 1.43 8/12
PB 1.74 10/12
PC 11.06 6/12
Liabilities to Equity 1.14 4/12
ROA -0.03 7/12
ROE -0.06 7/12
Current Ratio 1.88 9/12
Quick Ratio 0.14 9/12
Long Term Debt to Equity 0.78 3/12
Debt to Equity 0.81 4/12
Burn Rate 3.15 7/12
Cash to Cap 0.09 7/12
CCR -0.57 10/12
EV to EBITDA 53.62 6/12
EV to Revenue 1.97 8/12

Company Details

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

CEO: Mr. Vivek Jain

Website: https://www.icumed.com

Address: 951 Calle Amanecer San Clemente, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Medical Instruments & Supplies

ICU Medical, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to ICU Medical, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
DENTSPLY SIRONA Inc. XRAY $2.6 Billion
Hologic, Inc. HOLX $12.9 Billion
The Cooper Companies, Inc. COO $15.9 Billion
Haemonetics Corporation HAE $2.9 Billion
Merit Medical Systems, Inc. MMSI $5.4 Billion
AngioDynamics, Inc. ANGO $386.6 Million
AptarGroup, Inc. ATR $9.5 Billion
AtriCure, Inc. ATRC $1.6 Billion
Atrion Corporation ATRI $809.4 Million
Envista Holdings Corporation NVST $2.6 Billion
Akoya Biosciences, Inc. AKYA $54.1 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ICUI Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 629.8 Million -$23.8 Million
Q3 2024 $ 589.1 Million -$33.0 Million
Q2 2024 $ 595.8 Million -$21.4 Million
Q1 2024 $ 566.0 Million -$39.5 Million
Q4 2023 $ 587.9 Million -$17.1 Million
Q3 2023 $ 553.3 Million $7.2 Million
Q2 2023 $ 549.3 Million -$9.9 Million
Q1 2023 $ 568.6 Million -$9.8 Million

View All

ICUI Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $308.6 Million $4.2 Billion $1.6 Billion $2.0 Billion
Q3 2024 $312.5 Million $4.3 Billion $1.6 Billion $2.0 Billion
Q2 2024 $302.6 Million $4.3 Billion $1.7 Billion $2.0 Billion
Q1 2024 $251.4 Million $4.3 Billion $1.7 Billion $2.1 Billion
Q4 2023 $254.2 Million $4.4 Billion $1.6 Billion $2.1 Billion
Q3 2023 $197.2 Million $4.4 Billion $1.6 Billion $2.1 Billion
Q2 2023 $195.9 Million $4.5 Billion $1.6 Billion $2.1 Billion
Q1 2023 $220.9 Million $4.5 Billion $1.6 Billion $2.1 Billion

View All

ICUI Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 $13.6 Million -$26.6 Million -$3.9 Million
Q3 2024 $21.6 Million -$14.5 Million $9.9 Million
Q2 2024 $60.1 Million -$21.9 Million $51.2 Million
Q1 2024 $26.9 Million -$18.9 Million -$2.8 Million
Q4 2023 $31.2 Million $0 $31.2 Million
Q3 2023 $10.6 Million -$24.6 Million $1.3 Million
Q2 2023 -$21.9 Million -$20.4 Million -$25.1 Million
Q1 2023 $24.5 Million -$16.7 Million $12.2 Million

View All